News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rwanda, Merck & Co., Inc. (MRK) and QIAGEN Inc. (QGEN) Launch Africa‚Äôs First Comprehensive Cervical Cancer Prevention Program Incorporating Both HPV Vaccination and HPV Testing


4/25/2011 8:37:47 AM

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--The Government of Rwanda, together with QIAGEN N.V. (NASDAQ: QGEN, F:QIA) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

Read at BioSpace.com
Read at News Release
Read at Bloomberg
Read at Market Watch

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES